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Cutaneous squamous cell carcinoma of the head and neck is an epidemic that reaches all parts of the world. Making the diagnosis
reliesontheacumenoftheclinicianandpathologist.Variouspathologicsubtypesexistanddiﬀerinhistologyandprognosis.High-
risk tumors need aggressive treatment and vigilant surveillance to monitor for recurrence. Large tumors, deep tissue invasion,
perineural involvement, recurrence, location in high-risk areas, and immunosuppression are implicated in worsening prognosis.
Surgery is the mainstay of treatment with adjuvant radiation therapy as needed for aggressive tumors; however, other modalities
are potentially useful for low-risk lesions. The use of Mohs surgery has become increasingly useful and has shown high success
rates. Involvement of parotid and neck lymph nodes signiﬁcantly aﬀects outcomes and the physician should be comfortable with
management of this complex disease. This paper examines the diagnosis, pathology, clinical course, and treatment options for
cutaneous squamous cell carcinoma of the head and neck.
1.Introduction
Nonmelanoma skin cancer (NMSC) is the most common
type of cancer. The American Cancer Society estimates an
incidence of 1 million new cases per year in the United States
(US) [1]. Medicare fee for service procedures for skin cancer
increased 77% from 1992–2006 with 1.18 million patients
being aﬀected [2]. Extrapolation across the US population
using medicare data brings the total number of patients
treated for NMSC to over 2.1 million [2]. Cutaneous squa-
mous cell carcinoma (cSCC) is the second most common
skin malignancy in the US after basal cell carcinoma (BCC).
The annual incidence of cSCC is from 200,000 to 300,000
per year and constitute 20% of nonmelanoma skin cancers
[1]. Two thousand people die from NMSC each year in the
US [1]. Sun exposed areas are at risk for development of
disease with the head and neck having the highest incidence
[3]. Increasing rates of disease could be related to increased
sun exposure, ozone depletion, increasing length of life, and
changes in clothing style allowing more exposure [4–6].
Highest rates of disease are noted among white populations
with fair complexion, blue eyes, blonde or red hair, and in
those that burn or freckle easily with sun exposure [5]. The
majority of patients are men and the average age of onset is
66 [3]. The economic burden of skin cancer exceeds twenty-
ninebilliondollarsindirectmedicalcostsalonewithoverten
billion dollars lost to productivity opportunity cost [7]. The
common nature of the disease requires clinicians to remain
vigilant in surveillance and diagnosis. In this paper of cSCC
oftheheadandneck,riskfactors,pathology,diagnosticwork
up, and treatment are discussed.
2. Risk Factors
ThemostsigniﬁcantcontributiontocSCCisfromultraviolet
radiation (UVR) exposure. Although sunlight encompasses
several wavelengths, ultraviolet A and B light are the most
harmful to skin [5, 6, 8]. UVB light (200–320nm) is more
carcinogenic than UVA light (320–400nm), although both
can lead to malignancy [8]. In addition, the incidence
increases with age and cumulative sun exposure [5, 6, 8, 9].
Ultravioletexposurecausespyrimidinedimerformationthat
leads to point mutations in DNA and begins a cascade2 Journal of Skin Cancer
toward tumor formation [6, 8–12]. UVR can alter signal
transduction within cells and also aﬀect DNA repair mech-
anisms [10, 11]. The tumor-suppressor gene p53 has been
implicated in tumor generation as well. UVR can alter gene
activity in keratinocytes, allowing genetically altered cells to
avoid apoptosis [10, 13]. This transcription factor can be
inactivatedbydisruptionsinDNArepairorsinglenucleotide
mutations [10]. Oncogen activation of the ras pathway may
also be implicated in cSCC formation [10, 14]. Furthermore,
UVR acts as an immunosuppressant in the skin and fur-
ther deranges the normal defense against malignancy [15].
Congenital diseases, such as xeroderma pigmentosum and
oculocutaneous albinism, are autosomal recessive diseases
with increased incidences of skin malignancy. Defects in
DNArepairintheformerandthelackofmelanininthelatter
leave patients of both disease processes susceptible to UVR-
inducedcarcinogenesis[6].Xerodermapigmentosumcarries
a 2000-fold increased risk for cSCC [16].
Immunocompetence is vital in early cancer detection
anddestruction. Organtransplantrecipients (OTRs)havean
increased risk for development of skin cancers compared to
the normal population. Immunosuppression is an indepen-
dent predictor of survival [17, 18]. Renal transplant patients
were noted to have 18 to 36 times the frequency of cSCC
compared to the general public [9, 15]. In addition, the rate
of cSCC becomes greater than that of BCC—reverse that of
the normal population [19, 20]. An Irish study noted 50%
of skin cancers in OTRs were cSCC compared to 25% that
were BCC. The risk for cSCC in OTRs was 82 times greater
than in the general population [20]. This phenomenon
may be related to diﬀerences in major histocompatibility
complex—1 between the two types of cancer [21]. Immuno-
compromised patients treated for metastatic cSCC to the
parotid and neck have an increased risk of recurrence both
locally and distally posttreatment with markedly decreased
survival compared to immunocompetent individuals [22].
Southwell et al. describe a 0% two-year survival rate in
immune-deﬁcient patients compared to an 87% survival
in normal patients [22]. Organ transplant recipients have
an earlier age of onset of cSCC and a greater risk of
developing deeply invasive or aggressive cSCC at the time
of diagnosis [23]. In addition, Smith et al. noted increased
acantholysis, angiogenic components, and tumor thickness
histologically [23]. Recognition of the association of poor
immune function with cutaneous malignancy has led to
the creation of an international collaborative task force to
formulate guidelines of immunosuppression reduction in
transplantpatientsbasedontheseverityofskincancerdevel-
opment [24]. Patients with chronic lymphocytic leukemia
or lymphoma are also noted to have increased incidence of
cSCC [12, 25]. Mehramy et al. noted a recurrence rate 7
times that of controls in patients with chronic lymphocytic
leukemia [25].
Viral diseases may also play a role in the development of
NMSC.Individualswithhumanimmunodeﬁciencyvirusare
athighriskfordevelopingaggressivecSCC,withanincreased
risk of recurrence and metastasis [26]. Human papilloma
virus (HPV) has been implicated in the development of
cSCC as well [1, 15, 27, 28]. Susceptibility to HPV is
common in Epidermodysplasia verruciformis (EV) and has
been associated with NMSC [28, 29]. Multiple subtypes
compose the EV HPV group and are implicated in multiple
skin conditions [28]. Incorporation of viral DNA into the
genome of the cell or alteration of p53 is a potential
mechanism of action [15].
Chronic inﬂammation, scars and wounds are another
potential source of cSCC [5, 6, 8, 9, 12, 30]. No clear etiology
from scarring or chronic wounds exists to explain the
relationship with skin cancer. Possibilities include decreased
immune surveillance and changes in local circulation [9]. A
lack of early detection potentially explains the development
of high-risk disease in such patients [12]. In the African
American population, UVR plays a smaller role in cancer
arising from scarred skin in sites outside the head and neck,
and mortality from cSCC at these sites is greater than 18%
[30].
Other risk factors include chemical exposures from
tobacco, arsenic, and coal-tar products [5]. Ionizing radia-
tion from occupational or therapeutic exposure can also lead
to cSCC in a cumulative dose-dependent fashion [5, 6, 9].
3.Pathology
Multiple subtypes of cSCC exist. These subtypes diﬀer
histologically as well as prognostically. Cutaneous SCC
originates from keratinocytes in the spinous layer of the
epidermis. The most common form, or conventional type,
has atypical keratinocytes invading the dermis. In addition,
mitotic ﬁgures, hyperchromism, and pleomorphic nuclei are
seen. Keratin pearl formation and intercellular bridging is
common. This group of tumors can also be separated into
well, moderately, and poorly diﬀerentiated forms [12, 16,
31]. The spindle cell variant is uncommon and occurs in
UV damaged areas [32]. These tumors appear as ulcerated
nodules or exophytic lesions and have a tendency toward
perineural spread [12, 16, 32]. Furthermore, the spindle
cell variant has a lack of diﬀerentiation and can behave
aggressively while those not associated with radiation can
be more indolent [31, 32]. Immunohistochemistry shows
vimentin, cytokeratin, and epithelial membrane antigen
positivity [33] .T h ev e r r u c o u sv a r i a n to fc S C Ci sar a r e ,
low-grade disease presenting as a slowly enlarging, fungating
lesion [32]. The pushing nature of the lower epithelium as
broad projections into the dermis distinguishes this well-
diﬀerentiatedlesion[32].DesmoplasticcSCCisanaggressive
variant characterized by an invasive clinical course and poor
prognosis. Patients have 10 times the risk of local recurrence
and 6 times the risk of metastasis compared to other tumors
[34]. The tumor has a pronounced stromal component with
frequent perineural invasion and keratin pearls [31, 35].
Most cases are found on the ears, nose, and forehead [34].
4. ClinicalPresentation
Cutaneous squamous cell carcinoma presents as an erythe-
matous papule, plaque, or ulcer on a sun-exposed area of
the skin that does not heal. They can be friable and mayJournal of Skin Cancer 3
Table 1: Characteristics of high-risk tumors. Adapted from NCCN
PracticeGuidelinesinOncology:BasalCellandSquamousCellSkin
Cancers [36].
Size/Location:
(a) 10mm (cheeks, forehead, scalp, neck)
(b) 6mm3 (central face, eyelids, eyebrows, nose, lips, chin, ear,
temple)
Poorly deﬁned borders
Recurrent disease
Immunosuppression
Rapid Growth
Site of prior radiation, scar
Neurological symptoms
Pathologic Criteria:
(a)Moderately or poorly diﬀerentiated
(b) Adenoid (acantholytic), adenosquamous, or desmoplastic
(c) Depth:
Clark level IV, V
≥4mm
(d) Perineural or vascular invasion
bleed with manipulation. They can be painful at times [37].
Verrucous variants present as raised, slowly enlarging wart-
likelesionsthatmaybelocallyinvasive[37].Actinickeratoses
are precursor lesions that are scaly and vary in color and may
involute spontaneously over time. Hyperpigmented papules
can be seen in patients with bowenoid papulosis, while ﬂat
wart-likelesionsareseeninepidermodysplasiaverruciformis
[37]. Bowen’s disease is a form of in situ carcinoma with
scaly lesions and erythema on sun-exposed areas [37]. In
the head and neck, cSCC most commonly involves the ear,
frontotemporal region, and cheek [38] .H o w e v e r ,ar e c e n t
study from Australia implicated the nose as the predominant
site of disease [3].
5.ClinicalCourse
The extent of disease progression is dependent on the
timing of diagnosis and treatment. Late detection may be
complicated by more advanced disease and involvement of
regional lymphatics. Lesions on the cheek, pinna, temple,
forehead, anterior scalp, and postauricular area tend to
metastasize to the parotid basin and level II lymph nodes
[38, 40]. Tumors from the posterior scalp are more likely to
travel to level V while more anterior parts of the face often
bypasstheparotidandinvolvelevelsIandIII[38].Analyzing
the location of the lesion may help target lymph node basins
for metastasis. Risk factors for regional metastasis include
recurrence, size >2cm, depth of invasion, involvement of
deeperClarklevels,poordiﬀerentiation,perineuralinvasion,
acantholysis, inﬁltrative strands of tumor, and lesions from
existing scars [6, 8, 9, 12, 19, 41–43]. Moore et al. reviewed
the course of 193 patients with cSCC of the head and
neck and found that increased lymph node involvement
Table 2 :A J C CT N Ms t a g i n gf o rc S C C[ 39].
Primary tumor (T)
TX: Primary tumor cannot be assessed
T0: No evidence of primary tumor
Tis: Carcinoma in situ
T1: Tumor 2cm or less in greatest dimension with less than two
high-risk features∗
T2: Tumor greater than 2cm in greatest dimension or tumor any
size with two or more high-risk features∗∗
T3: Tumor with invasion of maxilla, orbit, or temporal bone
T4: Tumor with invasion of skeleton (axial or appendicular) or
perineural invasion of skull base
Regional Lymph Nodes (N)
NX: Regional lymph nodes cannot be assessed
N0: No regional lymph nodes
N1: Metastasis in a single ipsilateral lymph node, 3cm or less in
greatest dimension
N2a: Metastasis in a single ipsilateral lymph node, more than 3cm
but not more than 6cm in greatest dimension
N2b: Metastasis in multiple ipsilateral lymph nodes, none more
than 6cm in greatest dimension
N2c: Metastasis in bilateral or contralateral lymph nodes, none
more than 6cm in greatest dimension
N3: Metastasis in a lymph node, more than 6cm in greatest
dimension
Distant Metastasis (M)
M0: No distant metastasis
M1: Distant Metastasis
∗Excludes cSCC of the eyelid.
∗∗High-Risk Features for the Primary Tumor (T) staging: Depth/Invasion:
>2mm thickness, Clark level ≥IV; perineural invasion, Anatomic Location:
Primary site ear, Primary site hair-bearing lip, and Diﬀerentiation: Poorly
diﬀerentiated or undiﬀerentiated.
also occurred when pathological analysis revealed lympho-
vascular invasion [42]. A retrospective review by Cherpelis
et al. did not show increased metastatic spread associated
with ulceration or inﬂammation [41]. Identifying high-
risk lesions is vital to choosing an appropriate level of
aggressiveness during treatment. Throughout the literature,
high-risk cSCCs are recognized for their increased rates of
recurrence and metastasis. Multiple studies cite factors that
should be deemed high risk. The National Comprehensive
Cancer Network (NCCN) guidelines provide a consensus list
of factors to classify tumors as high risk [36]. Of note, the
size criteria vary depending on location, which diﬀers from
numerous studies that describe high-risk lesions as greater
than 2cm in diameter [6, 8, 9, 12, 19, 37, 41–45]. A modiﬁed
version of high-risk characteristics compiled by the NCCN is
listed in Table 1.
Traditionally, TNM staging for cSCC categorized lymph
node metastasis as either positive or negative, irrespective of
the involved nodal basins (parotid versus cervical). O’Brien
et al. prospectively monitored 87 patients with parotid gland
involvement. In their study, nodal disease was separated into
parotidandcervicalmetastasis.Parotidnodeswereseparated4 Journal of Skin Cancer
Table 3: AJCC Prognostic groups based on TNM staging [39].
Group T N M
0T i s N 0 M 0
IT 1 N 0 M 0
II T2 N0 M0
III T3 N0 M0
T1 N1 M0
T2 N1 M0
T3 N1 M0
IV T1 N2 M0
T2 N2 M0
T3 N2 M0
Ta n y N 3 M 0
T4 N any M0
T any N any M1
into nodes <3cm, nodes 3–6cm/multiple nodal disease,
or nodes >6cm/facial nerve or skull base involvement and
designated as P1, P2, or P3, respectively. Neck disease was
staged as N0 for no neck disease, N1 for a single node up
to 3cm in size, and N2 for disease >3cm or multiple or
contralateral nodes [46]. Parotid staging revealed positive
margins after parotidectomy increased as P stage increased.
In addition, patients with N2 disease had decreased survival
compared to patients with N0 and N1 disease [46]. The
presence of disease in both the parotid and neck signiﬁcantly
decreased survival compared to parotid disease alone. As
a result, O’Brien argued for P and N staging to better
assess prognosis in patients with lymph node metastasis
[46].Severalstudieshavealsoveriﬁedprognosticimportance
by separating nodal basin metastases [17, 18, 46–48]. In a
study of 67 consecutive head and neck cSCC patients in
New Zealand, Ch’ng et al. noted 37 patients with parotid
nodal metastases. P staging was a signiﬁcant independent
prognostic indicator of survival (P3 survival < P1, P2) [18].
In addition, the combination of positive parotid and cervical
nodes led to decreased survival compared to patients with
involvement of only one of these basins [18]. Palme et al.
retrospectively reviewed 126 patients with metastatic cSCC
and found 81 patients with parotid disease, 45 patients with
neck disease alone, and 14 patients with both. Increasing P
stage negatively impacted prognosis in a signiﬁcant fashion
with 5-year disease-speciﬁc survival for P1, P2, and P3 being
81%, 51%, and 33%, respectively [17].
To better assess prognosis by clinical stage, Forest et
al. have recently recommended changes to the P and N
staging system as they do not feel that the staging groups
have been adequately stratiﬁed or that the system adhered
well when applied to pathological data [48]. Instead of
separating parotid and cervical nodal metastases, Forest
suggests including the groups together and stratifying based
on number and size of nodes. This system, referred to as
N1S3, classiﬁes nodal metastases into three separate stages.
The ﬁrst stage includes patients with single lymph nodes up
to 3cm in size. Stage II encompasses single nodes >3cm
or multiple nodes up to 3cm in size. Stage III patients
have multiple lymph nodes greater than 3cm [48]. The
American Joint Commission on Cancer updated the staging
system for cSCC in an eﬀort to include more speciﬁc
factors in prognosis. The AJCC system incorporates high-
risk characteristics as well as a neck staging system similar to
other head and neck malignancies. The AJCC system is listed
in Table 2 [39]. Prognostic groups are included in Table 3
[39].
6.Diagnosis
Diagnosis of cSCC requires a total body skin examination.
In addition, head and neck disease necessitates a complete
head and neck physical examination. Suspicious lesions need
biopsies that incorporate the depth of the lesion beyond
superﬁcial sampling. In areas that are close to vital structures
or may impede cosmesis, incisional or punch biopsies may
be taken. These biopsies should include the dermis and
allow the presence of malignancy to be conﬁrmed before a
larger resection is performed. For smaller lesions away from
critical areas, an excisional biopsy of the area allows for a
diagnostic and potentially therapeutic procedure. If a lesion
is suspicious for deeper invasion or regional metastasis,
imaging may become necessary. CT scanning may be helpful
in determining whether there is bony involvement, while
magnetic resonance imaging is better for assessing nerve and
potential dural spread.
7. Treatment
The mainstay of treatment for cSCC is surgical resection.
However, other modalities of therapy are present throughout
the literature. Fluorouracil (5-FU) is a topical chemotherapy
agent that has approval in the United States by the Food
and Drug Administration for treatment of actinic keratoses.
It works by disrupting DNA synthesis and results in cell
death. The use of 5-FU for cSCC is not recommended or
widely utilized as a treatment for cancer [49]. Imiquimod
is a synthetic agent used as an immune response modiﬁer
by stimulating cell surface receptors and increasing cytokine
release [49]. Although its use in basal cell carcinoma is being
studied, the appropriateness for cSCC is not supported and
shouldnotbeused.Reportsofoﬀ-labeluseforinsitudisease
outside of the head and neck have been reported with success
and with further investigation may be found to be useful for
noninvasive disease [50, 51].
Photodynamic therapy (PDT) is another treatment class
that is being studied in the treatment of cSCC. PDT involves
injecting a hematoporphyrin derivative into the bloodstream
and treating with light therapy several hours after. The light
is directed toward the area of malignancy or precancerous
change to react with the photosensitizing agent to cause
cell death with minimal disruption to normal skin [52]. In
their guidelines for use of PDT for NMSC, Braathen et al.
support the use of PDT for actinic keratosis and Bowen’s
disease as ﬁrst line therapy. The group does not feel there is
ample evidence to support its use for invasive cSCC [53]. An
Austrian study noted a complete response in 54% of patientsJournal of Skin Cancer 5
with superﬁcial cSCC with a recurrence rate of 69% after a
median followup of 8 months [54]. Schweitzer suggests use
of photofrin-mediated PDT for elderly patients with large
or multifocal recurrent lesions when surgical resection is
contraindicated due to location or morbidity [52, 55].
Electrodesiccation and curettage can be used for small,
superﬁcial, well-deﬁned lesions. This technique involves
tumor removal down to the dermis and is practitioner
dependent. Tumor extension into the subcutaneous fat
requiresamoreformalsurgicalresection.Goldmandescribes
a lower recurrence rate on the trunk and extremities
secondary to a thicker dermis allowing better “feel” during
curettage [56]. Werlinger et al. describe its use for cSCC,
with 2 cases of recurrence after treatment of 56 patients
compared to no recurrences with surgical excision. Average
tumor size in the study was 7.9mm [57]. Because recurrence
rates are greater in higher risk tumors, electrodesiccation
and curettage is reserved for small, superﬁcial tumors in
noncosmetically important areas [58]. Cryosurgery also can
be used for low-risk, superﬁcial disease. Curettage can
precede cryotherapy without changes in eﬀectiveness [59].
Kuﬂik describes the use of cryotherapy for NMSC over a
30-year period. In his study, most lesions ranged from 0.5
to 2cm in size and had high cure rates [59]. Cryosurgery
should not be used for high-risk tumors and has worse
cosmetic outcomes compared to surgical excision [58, 60].
Am a j o rd i s a d v a n t a g ef o rb o t hc r y o s u r g e r ya sw e l la s
electrodesiccationandcurettageisthelackofmarginanalysis
during resection.
The use of primary radiotherapy (RT) in patients with
cSCC depends on multiple factors including cosmesis,
function, age, medical morbidity, and patient desire [61,
62]. Disadvantages include cost, no histological control, and
potential for side eﬀects and secondary malignancy [61–63].
Local tumor control in small lesions rivals that of surgical
resection, even in recurrent disease [61, 63]. However, as T
stage increases, local control decreases [63]. In older patients
withmajorcosmeticandfunctionaldisturbancewithsurgery
andreconstruction,radiotherapycanbeanattractiveoption.
In addition, patients with unresectable disease may beneﬁt
from RT. Al-Othman et al. treated 88 T4 basal cell and
squamous cell carcinomas using RT with curative intent.
Local control was 53% at 5 years; however, including surgical
salvage increased this ﬁgure to 90% [64]. Patients with
tumor involving bone had lower survival rates or increased
risk of bone complications [64]. In patients with regional
metastasis, the use of surgery followed by RT is preferred to
RT alone [17, 42, 47, 65–67]. Multiple studies have noted
decreased disease-speciﬁc survival in patients treated with
RT alone [65–67]. A University of Florida study found a
72% 5 year disease speciﬁc survival in patients treated with
surgery and postoperative RT compared to 59% treated with
RT alone [67]. In a separate study, 5-year local control rates
were 83% with surgery followed by RT compared to 47%
for RT alone [47]. Combined therapy allows for decreased
recurrence rates and increased disease-free survival versus
e i t h e rR To rs u r g e r ya l o n e[ 65]. Use of RT in patients with
recurrence, perineural invasion, advanced disease, disease
along embryonic fusion planes, and positive margins should
be strongly considered [62, 68, 69]. Younger patients with
a long life expectancy should avoid RT as a single modality
because of the potential for late complications and decline in
cosmesis over time [61].
Surgical resection with pathological monitoring remains
the primary method of treatment for cSCC of the head
and neck. Careful consideration of tumor margins, size of
resection, as well as potential for reconstruction, functional
deﬁcit and cosmesis must be considered and thoroughly
discussed before proceeding. Appropriate surgical margins
forcSCCare4mmforlow-risklesions[70,71].Thisnumber
is the minimal margin necessary to achieve greater than a
95% tumor clearance rate as determined by Brodland and
Zitelli using Mohs micrographic surgery (MMS) [71]. A
margin of 6mm is suggested for higher-risk lesions [71].
The NCCN guidelines recommend 4–6mm margins for
low-risk tumors [36]. Larger margins, MMS, or complete
circumferential peripheral and deep margin assessment with
frozen section analysis is needed for higher risk lesions
[36]. Brodland and Zitelli’s criteria for high-risk lesions
include tumor diameters >2cm, higher histologic grade,
subcutaneous tissue invasion, and location in high-risk areas
(scalp, eyelids, ears, nose, and lips) [71]. Recurrence rates
for conventional resection are reported in Rowe’s review
of treatment techniques as 8% over 5 years [19]. Griﬃths
et al. followed 93 patients after conventional resection and
found 85 patients alive and disease free after 5 years resulting
in a 91.4% disease speciﬁc survival [72]. Brantsch et al.
used 3D-histology with surgical excision and followed 615
patients over an average of 43 months [73]. Local recurrence
was 3% and depended on tumor thickness and amount of
desmoplasia. A thickness of 2mm or less, 2.1 to 6mm, or
>6mm locally recurred in 0.5, 2.5, and 12.2% of patients,
respectively [73]. Metastatic rate for tumors less than 2cm
was 1.9% versus a rate of 7.5% in lesions greater than 2cm
in size [73]. Metastasis-free survival over 6 years was 98%
in patients with lesions less than 6mm thickness without
desmoplasia (low-risk). High-risk tumors with desmoplasia
and thickness greater than 6mm had a recurrence rate of
75% [73]. Again, the more high-risk the tumor, the greater
the risk of recurrence and metastasis.
Surgical resection using Mohs micrographic surgery
provides a high cure rate with an emphasis on tissue
conservation [3].Theprocessinvolvesserialsectioningofthe
tissue with comprehensive analysis of the tumor margins via
horizontal frozen sections, allowing for greater assessment of
theperipheralanddeepsurgicalmargins.Traditionalvertical
histologic sectioning techniques assess only a fraction of the
margins to be visualized [3]. Sectioning of the tissue into
quadrants and creating a tumor map with strict orientation
to sectioning allows excellent assessment of lateral and
deep margins. MMS allows better mapping than traditional
excision, and repeat sectioning only occurs in areas with
cancer to allow better tissue preservation. As a result, MMS
is ideal for high-risk tumors and lesions in the cosmetically
and functionally important areas of the eyes, nose, and lips.
Preservation of form and function is essential when near the
canthal apparatus of the eye, the oral commissure of the lip,
and the ala of the nose. In tumors with deep extension, more6 Journal of Skin Cancer
invasive resection may become necessary to augment MMS.
A prospective, multicenter case series in Australia over 10
years of MMS reviewed 1263 patients with squamous cell
carcinoma. The technique had a 5-year recurrence rate of
3.9% [3]. Recurrent tumors had a higher recurrence rate
of 5.9% compared to 2.6% of primary tumor excisions [3].
Recurrence rates in patients with perineural invasion were
h i g h e s ta t8 %o v e r5y e a r s[ 74]. Perineural invasion most
often occurred in moderately to poorly diﬀerentiated tumors
with larger tumor sizes, subclinical extension, and a higher
number of MMS levels needed for excision [74]. Clinical
perineural involvement had worse survival and control rates
compared to those with incidental invasion found [3].
Because of the high cure rates and importance placed on
tissue conservation, MMS remains an important tool in the
treatment of high-risk cSCC [3, 12, 19, 62].
8.TreatmentoftheParotidandNeck
Treatment of the lymph node basins draining cSCC primary
sites is important to consider in high-risk, aggressive tumors.
Various tumor sites require diﬀerent levels to be included
in selective neck dissection. Classically, tumors anterior to
the external auditory canal require superﬁcial parotidectomy
a n dc e r v i c a ln e c kl e v e l sI It oI V ,w h i l ep o s t e r i o rl e s i o n s
require a posterolateral neck dissection in addition to levels
II to IV. If the medial orbits, midface, or lips are involved,
bilateral supraomohyoid neck dissections are needed [75–
77]. Every cervical neck dissection should include the
external jugular node as described by O’Brien, regardless of
the site of lesion [40, 77]. Although elective neck dissections
can be argued to be unnecessary since cSCC is a common
tumor with uncommon neck disease, occult disease has been
encountered [38]. Regional metastatic disease varies in the
literature from 4% to 5.8% and has been noted to be as high
as 20.7% [42, 73, 78]. The risk of metastasis to lymph nodes
is related to risk factors such as increased tumor thickness,
increased diameter, immunosuppression, arising from scars,
and involvement of the ear [19, 73, 79]. Patients with
lymphovascular invasion, poorly diﬀerentiated histology,
perineural invasion, and subcutaneous invasion also have
increased risk of metastasis [42]. Although controversial,
elective neck dissection has a utility as a staging procedure
and can help decision making regarding adjuvant therapy.
In addition, for higher risk patient groups or tumors with
extensionintosofttissue,electiveneckdissectioncanbecon-
sidered [80]. Fine needle aspiration of suspicious nodes can
be helpful to determine the need for neck dissection [36]. To
better assess lymph node involvement, lymphatic mapping
with sentinel lymph node biopsy (SLNB) is being investi-
gated [81, 82]. Civantos et al. performed SLNB in patients
that met high-risk criteria for cSCC. Their criteria included
size >2cm; evidence of deep invasion; immunosuppression;
ear,lip,nasalvestibularlocationortumorarisingfromascar;
high grade pathologic features; or rapid growth [82]. The
negative predictive value was 98% and the false negative rate
was 17% for skin disease [82]. Altinyollar studied 20 patients
with lower lip lesions greater than 2cm in size without
palpable nodal disease. SLNB revealed no false positives, and
disease was found in 16.6% of patients [83]. Renzi et al.
noted all positive disease found with SLNB in their case
series and those reviewed from the literature to have a size
greater than 2cm [84]. Most studies have small numbers and
have varying deﬁnitions of high-risk patients necessitating
SLNB. Furthermore, prospective multi-institutional studies
are needed to verify the independent eﬀect of speciﬁc risk
factors for metastasis [80, 84, 85]. Use of SLNB for cSCC
may be limited due to less metastatic spread compared to
melanoma[38].FurtherstudyofSLNBisnecessarybeforeits
universal application in the management of high-risk cSCC
[86].
Clinical nodal disease in the parotid and neck should
be addressed therapeutically. Metastatic disease aﬀects the
parotid gland in 60% to 82% of those patients with nodal
spread [38, 87]. Cervical neck node disease without parotid
involvement can be seen in 18 to 41% of patients [38,
87, 88]. In patients with positive parotid disease, spread to
the cervical nodes can be occult, ranging from 16 to 42%,
illustrating the importance of management of cervical nodes
even if clinically negative [42, 66, 87]. Regional management
of potential occult cervical nodes in those with known
parotid disease is highly recommended.
Patients with positive lymph node disease have recur-
rence rates posttreatment ranging from 28% to 33% [46,
66, 87, 88]. Moore et al. examined 167 patients with nodal
disease secondary to cSCC. Patients with combined surgery
and RT had a 5-year local recurrence rate of 20% compared
to 43% of patients with surgery alone. Disease-free survival
at 5 years was also improved with combined therapy at
a rate of 73% versus 54% of those with single modality
therapy. Median time to recurrence was 8 months with
73% of locoregional failures eventually dying of disease [87].
Postoperative radiation is recommended in patients with
regional disease. In a study of 74 patients with regional
disease only to cervical nodes, Veness et al. found a 34%
recurrence rate in a median time of 5.2 months with 4%
being distant metastases [65]. In this study, disease speciﬁc
survival was signiﬁcantly higher in those receiving surgery
and radiation compared to surgery or radiation treatment
alone [65]. Andruchow et al. reviewed 322 patients with
cSCC and lymph node metastasis with 90% treated with
surgery and RT. Of the 105 recurrences, 42 occurred in
the parotid, 33 presented in the neck, and 30 were distant
metastases [88]. The importance of continued surveillance
posttreatment of nodal disease is vital despite the advised
combined modality therapy with surgery and radiation.
Conﬂicting data in the literature exists in regards to
the prognostic diﬀerence between parotid node and cervical
node disease. Positive disease in both parotid and cervical
nodeshasshownworseprognosisthanindividualareasbeing
aﬀected in some studies [18, 88]. However, Palme et al. have
shown similar survival rates regardless of location of disease
and Moore et al. noted no diﬀerence in recurrence rates
[17, 87]. The N1S3 staging system suggests that the presence
of regional disease alone is the most critical factor, regardless
of location in the parotid or cervical basins [48]. Location
also does not alter how multiple nodal disease, nodal sizeJournal of Skin Cancer 7
3cmorgreater,andextracapsularspreadalldecreasesurvival
[18, 46, 48, 65].
The presence of high recurrence rates with high-risk
disease and nodal metastasis has increased the need for
further avenues of therapy. The addition of chemotherapy
to surgery and RT is now under evaluation [89]. NCCN
guidelines recommend combined radiation and cisplatin for
incompletely excised nodal disease and possible use in those
with extracapsular nodal extension [36]. Evidence for use is
based on results from mucosal squamous cell carcinoma of
the head and neck and not from prospective, randomized
trials speciﬁcally for cSCC [36, 90–92]. Use of 5-ﬂuorouracil,
doxorubicin, or bleomycin added to cisplatin can be used
in cases of regional recurrences or distant metastases, but,
has little supporting data [36]. Additionally, case reports
of cetuximab as therapy have shown some potential for
future use [93–95]. This agent is a monoclonal antibody
targeting epidermal growth factor receptor (EGFR). The
increased expression or dysregulation of EGFR in NMSC
makes use of cetuximab an attractive avenue of research
for treatment of cSCC [96, 97]. Anti-insulin-like growth
factorantibodywithanti-EGFRantibodyhasshowninduced
apoptosis in vitro and improved survival in mice with
cSCC [98]. Future avenues of therapy with monoclonal
antibodies are becoming increasingly more studied for use in
cSCC.
9.Followup
Patient followup for local disease includes visits every 3–6
months for 2 years, 6–12 months for 3 years, and annually
thereafter [36]. Patients with regional disease or from high
risk groups require followup every 1–3 months during year
1, every 2–4 months during year 2, every 3–6 months
during years 3–5, and ﬁnally every 6–12 months thereafter.
Certain high-risk populations (immunosuppression, OTRs,
xerodermapigmentosum,etc.)necessitatetitratingexamina-
tions to disease frequency. All patients should be educated
regarding sun protection and self-examination [36].
10. Conclusion
Treatmentofcutaneoussquamouscellcarcinomarequirethe
physician to be familiar with the characteristics of high-risk
tumors and patient groups. Surgical resection remains the
treatment of choice and MMS is especially useful in high-
risk patients or in functional and cosmetic areas. Aggressive
tumors metastasizing to the neck requires consideration of
multimodal therapy with surgery and radiation. Chemother-
apy is potentially useful in cases of extracapsular extension
or in residual neck disease. Close surveillance, especially
within the ﬁrst two years after treatment, is recommended.
Continued research is necessary to assess the utility of
nonsurgical modalities of treatment as well as the use of
sentinel lymph node sampling. Anti-EGFR antibodies have
shown eﬀectiveness with other cancers of the head and neck
and have potential in treating cSCC in the future.
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